S
002880
vs
S
Shanghai Composite
Over the past 12 months, Shenzhen Weiguang Biological Products Co Ltd has underperformed Shanghai Composite, delivering a return of +8% compared to the Shanghai Composite's +23% growth.
Stocks Performance
002880 vs Shanghai Composite
Performance Gap
002880 vs Shanghai Composite
Performance By Year
002880 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shenzhen Weiguang Biological Products Co Ltd
Glance View
Shenzhen Weiguang Biological Products Co., Ltd. engages in the manufacturing, research and development of drug and blood products. The company is headquartered in Shenzhen, Guangdong and currently employs 759 full-time employees. The company went IPO on 2017-06-16. The Company’s primary products are blood products, including the human serum albumin, human immunoglobulin, intravenous human immunoglobulin, freeze-dried intravenous human immunoglobulin, hepatitis B human immunoglobulin, Rabies immunoglobulin, tetanus immunoglobulin, histamine human immunoglobulin, and human fibrinogen. The firm mainly operates its businesses in domestic market.
